GlassScriptPhysician profile
Lauren Davis
NPI 1922576941
$4,245.00
in general payments reported to CMS, 2019-2025
21 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $404 · 2022: $359 · 2023: $963 · 2024: $1,262 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,367.57 |
| Education | $114.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,007.94 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $658.64 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $448.69 | 2021-2025 | Takhzyro, Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $419.66 | 2021-2025 | Dupixent |
| Csl Behring | $397.91 | 2021-2025 | Haegarda, Hizentra |
| Amgen INC. | $183.85 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $177.89 | 2022-2025 | Xembify, Gamunex-C |
| Ars Pharmaceuticals Operations, INC. | $141.02 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $140.99 | 2023-2025 | |
| Abbvie INC. | $121.09 | 2024 | |
| Glaxosmithkline, LLC. | $108.60 | 2021-2023 | Nucala |
| Organon LLC | $106.62 | 2025 | Vtama |
| Pfizer INC. | $60.85 | 2022-2024 | |
| Hikma Pharmaceuticals USA | $54.78 | 2023 | Ryaltris |
| Kaleo, INC. | $47.85 | 2022-2024 | Auvi-Q |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $41.59 | 2024-2025 | Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $34.55 | 2021-2024 | Xolair |
| Pharming Healthcare, INC. | $29.27 | 2024 | Ruconest |
| Blueprint Medicines Corporation | $24.33 | 2024 | Ayvakit |
| Biocryst US Sales Co., LLC | $22.61 | 2025 | Orladeyo |
| Biohaven Pharmaceuticals, INC. | $16.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.